On natural and artificial vaccinations
- PMID: 12500980
- DOI: 10.1146/annurev.immunol.21.120601.141045
On natural and artificial vaccinations
Abstract
This review summarizes the general parameters of cell- and antibody-mediated immune protection and the basic mechanisms responsible for what we call immunological memory. From this basis, the various successes and difficulties of vaccines are evaluated with respect to the role of antigen in maintaining protective immunity. Based on the fact that in humans during the first 12-48 months maternal antibodies from milk and serum protect against classical acute childhood and other infections, the concept is developed that maternal antibodies attenuate most infections of babies and infants and turn them into effective vaccines. If this "natural vaccination" under passive protective conditions does not occur, acute childhood diseases may be severe, unless infants are actively vaccinated with conventional vaccines early enough, i.e., in synchronization with the immune system's maturation. Although vaccines are available against the classical childhood diseases, they are not available for many seemingly milder childhood infections such as gastrointestinal and respiratory infections; these may eventually trigger immunopathological diseases. These changing balances between humans and infections caused by changes in nursing habits but also in hygiene levels may well be involved in changing disease patterns including increased frequencies of certain autoimmune and degenerative diseases.
Similar articles
-
On immunity against infections and vaccines: credo 2004.Scand J Immunol. 2004 Jul-Aug;60(1-2):9-13. doi: 10.1111/j.0300-9475.2004.01460.x. Scand J Immunol. 2004. PMID: 15238068 Review.
-
Can infants be protected by means of maternal vaccination?Clin Microbiol Infect. 2012 Oct;18 Suppl 5:85-92. doi: 10.1111/j.1469-0691.2012.03936.x. Epub 2012 Aug 6. Clin Microbiol Infect. 2012. PMID: 22862749 Review.
-
Differential approaches for vaccination from childhood to old age.Gerontology. 2013;59(3):230-9. doi: 10.1159/000343475. Epub 2012 Nov 24. Gerontology. 2013. PMID: 23183353 Review.
-
Immunopathology of RSV infection: prospects for developing vaccines without this complication.Rev Med Virol. 2007 Jan-Feb;17(1):5-34. doi: 10.1002/rmv.518. Rev Med Virol. 2007. PMID: 17004293 Review.
-
Vaccination of neonates: problem and issues.Vaccine. 2012 Feb 21;30(9):1541-59. doi: 10.1016/j.vaccine.2011.12.047. Epub 2011 Dec 18. Vaccine. 2012. PMID: 22189699 Review.
Cited by
-
Salmonella porins induce a sustained, lifelong specific bactericidal antibody memory response.Immunology. 2006 Jan;117(1):59-70. doi: 10.1111/j.1365-2567.2005.02263.x. Immunology. 2006. PMID: 16423041 Free PMC article.
-
Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells.Cancer Immunol Immunother. 2006 Oct;55(10):1209-18. doi: 10.1007/s00262-005-0106-6. Epub 2005 Dec 6. Cancer Immunol Immunother. 2006. PMID: 16331519 Free PMC article. Clinical Trial.
-
Harnessing Nanoparticles for Immunomodulation and Vaccines.Vaccines (Basel). 2017 Feb 14;5(1):6. doi: 10.3390/vaccines5010006. Vaccines (Basel). 2017. PMID: 28216554 Free PMC article. Review.
-
Toxoid Vaccination against Bacterial Infection Using Cell Membrane-Coated Nanoparticles.Bioconjug Chem. 2018 Mar 21;29(3):604-612. doi: 10.1021/acs.bioconjchem.7b00692. Epub 2017 Dec 27. Bioconjug Chem. 2018. PMID: 29241006 Free PMC article. Review.
-
Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trial.Hum Vaccin Immunother. 2022 Nov 30;18(6):2122503. doi: 10.1080/21645515.2022.2122503. Epub 2022 Oct 31. Hum Vaccin Immunother. 2022. PMID: 36315843 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous